ClinicalTrials.gg
Active, not recruitingNCT06561607Updated Sep 10, 2026

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

A Phase 3 interventional study of TQB2102 for Injection and Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 34 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
4th of 28
542 · median 138
Started
2024
with 3 others
Phase 3
11 of 28
5 open now
Primary completion
2027-01
later than 9 of 15 live
Registered
19th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is one of 11 in phase 3, reaches primary completion later than 9 of the 15 other live ones, and was the 19th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, paclitaxel, or albumin-paclitaxel) until progression of disease (PD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1, unless there are unacceptable toxicity, withdrawal of consent, or meeting other discontinuation criteria.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily enrolled in this study with good compliance;
  • Age: 18-75 years old; Performance Status (ECOG PS) score: 0-1;
  • confirmed locally advanced or breast cancer with low expression and unresectable:
  • Defined hormone receptor (HR) status.
  • Imaging-confirmed disease progression (during or after completion of the most recent treatment);
  • Have at least one according to 1.1 criteria;
  • Good major organ function.

Exclusion criteria

Exclusion Criteria:

  • The presence or current concurrent presence of other malignant tumors within 5 years prior to randomization. ;
  • Unresolved toxic reactions above Common Terminology Criteria (CTC) for Adverse Events (AE) grade 1 due to any prior therapy;
  • Major surgical treatment, incisional , or significant traumatic injury within 28 days prior to the start of the pre-randomization period;
  • Prolonged unhealed wounds or fractures;
  • Previous history of interstitial lung disease/pneumonia requiring steroidal drug intervention;
  • The presence of moderate to severe pulmonary dysfunction/disease within 3 months prior to randomization;
  • The presence of an arterial/deep vein thrombotic event within 6 months prior to randomization;
  • The presence of a medical condition that interferes with intravenous administration, intravenous blood collection, or inability to swallow, chronic diarrhea, intestinal obstruction, or the presence of other factors that interfere with the administration and absorption of medications;
  • The presence of grade ≥2 myocardial ischemia or myocardial infarction, cardiac arrhythmias (including corrected (QTc) ≥450ms (men) and QTc ≥470ms (women)) and grade ≥2 congestive heart failure ( (NYHA) classification); angina pectoris requiring antianginal medication; and heart valve disease;
  • Active or uncontrolled ≥ CTC AE grade 2 infection present within 14 days prior to randomization;
  • Cirrhosis of the liver, active hepatitis that is not well controlled;
  • Renal failure requiring hemodialysis or peritoneal dialysis;
  • History of immunodeficiency, including -positive or other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
  • Those with routine urinalysis suggestive of urinary protein ≥++ and confirmed 24-hour urine protein quantification >1.0 g;
  • Those who have used or systemic hormone therapy for immunosuppression within 2 weeks prior to randomization;
  • Those with a history of psychotropic substance abuse that cannot be abstained from or those with psychiatric disorders;
  • Tumor-related symptoms and treatments:

    1. Subjects who have been treated with other antineoplastic agents such as chemotherapy, radical radiotherapy, or immunotherapy within 4 weeks prior to randomization, or who are still within 5 half-lives of the drug (whichever occurs shortest);
    2. Treatment with endocrine therapy, molecularly targeted therapy, or a proprietary Chinese medicine with an anti-tumor indication as specified in the National Medical Products Administration (NMPA) approved drug insert within 2 weeks prior to randomization;
    3. Presence of carcinomatous lymphadenitis, or uncontrollable pleural effusion, ascites, and pericardial effusion of moderate volume or greater that requires repeated drainage to relieve clinical symptoms, or who have received drainage of plasmapheresis for therapeutic purposes within 2 weeks prior to randomization;
    4. Known carcinomatous meningitis or clinically active central nervous system ;
    5. Severe bone damage resulting from tumor bone metastases;
  • Those who have received a control chemotherapeutic agent of the investigator's choice during the recurrent metastatic phase or for whom a control chemotherapeutic agent of the investigator's choice is inappropriate for reasons such as intolerance or to that agent;
  • Has received prior anti- therapy;
  • Who have developed to humanized monoclonal antibody products;
  • Those who have developed an allergy to any of the study drugs or any component or in the drugs;
  • Who have participated in and used another antitumor clinical trial drug within 4 weeks prior to randomization;
  • Subjects who, in the judgment of the investigator, have a concomitant disease that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or who are deemed to have other reasons for being unsuitable for enrollment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
542 participants (estimated)

Study arms

  • Experimental
    TQB2102 for Injection

    Administered by intravenous drip, 7.5 mg/kg per dose, 21 days as a treatment cycle.

    Drug: TQB2102 for Injection

  • Active comparator
    Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

    Based on each patient's condition and previous treatment history, the investigator will select one of the following chemotherapy drugs for treatment. * Capecitabine * Paclitaxel * Albumin Paclitaxel

    Drug: Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

Interventions

  • DrugAnti-HER2/Topoisomerase I Inhibitor ADC TQB2102Studies of Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.

  • DrugChemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

    Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment. * Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle. * Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly. * Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)

    Designed to demonstrate that in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer, TQB2102 for injection significantly prolongs progression-free survival in subjects compared to investigator-selected chemotherapy.

    Time frame: Up to 25 months

Secondary outcomes

  1. Progression-free survival (PFS) in subjects with HER2 low-expressing recurrent/metastatic breast cancer as assessed by IRC

    Designed to demonstrate that in subjects with HER2 low-expressing recurrent/metastatic breast cancer, TQB2102 for injection significantly prolongs progression-free survival in subjects compared to investigator-selected chemotherapy.

    Time frame: Up to 25 months

  2. Progression-free survival (PFS) as assessed by investigators in the HR-positive, HER2 low-expressing population

    To evaluate progression-free survival (PFS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  3. Investigator-assessed overall survival (OS) in HR-positive, low HER2-expressing population.

    To evaluate the overall survival (OS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  4. Overall survival (OS) as assessed by investigators in the HR-positive, HER2 low-expressing population

    To evaluate the objective remission rate (ORR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  5. Duration of remission (DOR) as assessed by investigators in the HR-positive, HER2 low-expressing population

    To evaluate the duration of remission (DOR) of injectable TQB2102 compared to investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  6. Investigator-assessed clinical benefit rate (CBR) in the HR-positive, low HER2-expressing population

    To evaluate the clinical benefit rate (CBR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  7. Progression-free survival (PFS) as assessed by investigators in the HER2 low expression population

    To evaluate progression-free survival (PFS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  8. Overall survival (OS) as assessed by investigators in the HER2 low expression population

    To evaluate the overall survival (OS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  9. Duration of remission (DOR) as assessed by investigators in the HER2 low expression population

    To evaluate the duration of remission (DOR) of injectable TQB2102 compared to investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  10. Objective remission rate (ORR) as assessed by investigators in the HER2 low expression population

    To evaluate the objective remission rate (ORR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  11. Clinical benefit rate (CBR) as assessed by investigators in the HER2 low expression population

    To evaluate the clinical benefit rate (CBR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Up to 25 months

  12. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and indicators of abnormal laboratory tests

    To evaluate the safety of TQB2102 for Injection compared to investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer, including: the incidence and severity of adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs).

    Time frame: Up to 52 months

  13. Blood concentrations of the Antibody-Drug Conjugate (ADC) drug TQB2102, total antibodies, and the small molecule toxin TQ22723

    To evaluate the pharmacokinetic (PK) profile of TQB2102 for injection in subjects with HER2 low-expressing recurrent/metastatic breast cancer. Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12, and 0.5 to 2 hours after the end of infusion for Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12 .

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12, and 0.5 to 2 hours after the end of infusion for Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12 (21 days as a treatment cycle).

  14. Immunogenicity of TQB2102: ADA incidence

    To evaluate the immunogenicity (ADA) of TQB2102 for injection in subjects with HER2 low expression recurrent/metastatic breast cancer.

    Time frame: Prior to (-60 min) the first day of dosing in Cycle 1, Cycle 2, Cycle 4, Cycle 7, and Cycle 12 (21 days as a treatment cycle), and at follow-up 30 days (±7 days) after the last dosing.

07

Study locations

34 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 27 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 20, 2024
StartActual
Oct 11, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06561607
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Oct 11, 2024
Primary completion
Jan 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion